Get notified when BIAF files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Use of Proceeds Section Is Empty (new) — The company has not disclosed how it will use the $2.96 million in net proceeds, leaving investors without clarity on capital allocation.
bioAffinity Technologies prices $3.2M offering of 1.04M shares at $0.80, plus pre-funded warrants
Filed June 18, 2026 · ~1 min read
Key Changes
-
high
bioAffinity Technologies is offering 1,040,000 shares of common stock at $0.80 per share, with gross proceeds of $3.2 million.
The Offering verify on EDGAR → -
high
The company is also offering pre-funded warrants to purchase up to 2,960,000 shares at $0.007 per share, for purchasers who would otherwise exceed ownership limits.
The Offering verify on EDGAR → -
high
After placement agent fees of $238,446 (7.5% of gross proceeds), net proceeds to the company before other expenses are approximately $2.96 million.
The Offering verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade BIAF commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify